This brand name is authorized in Australia, Estonia, Israel, New Zealand
The drug PHENASEN contains one active pharmaceutical ingredient (API):
|
1
Arsenic trioxide
UNII S7V92P67HO - ARSENIC TRIOXIDE
|
|
Arsenic trioxide causes morphological changes and deoxyribonucleic acid (DNA) fragmentation characteristic of apoptosis in NB4 human promyelocytic leukaemia cells in vitro. Arsenic trioxide also causes damage or degradation of the fusion protein PML/RAR alpha. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| L01XX27 | Arsenic trioxide | L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XX Other antineoplastic agents |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: AU | Pharmaceutical Benefits Scheme | Identifier(s): 10691Q, 10699D, 4371C, 7241D |
| Country: EE | Ravimiamet | Identifier(s): 1773862 |
| Country: IL | מִשְׂרַד הַבְּרִיאוּת | Identifier(s): 8748 |
| Country: NZ | Medicines and Medical Devices Safety Authority | Identifier(s): 19218 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
